Intradetrusor injection of botulinum toxin A in children: a 10-year single centre experience

Peeraully, Riyad; Lam, Christine; Mediratta, Nikita; Patel, Ramnik V; Williams, A.R.; Shenoy, Manoj; Fraser, Nia

doi:10.1007/s11255-019-02185-3

Cited by 7 publications

(27 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Botulinum toxin A significantly improve all symptoms and urodynamic parameters in NDO and OAB in this study, this effect was reported in previous study which demonstrated similar in children and adults alike [1,5]. The effect of Botox A in treating lower urinary tract dysfunction appears to be overestimated further.…”

Section: Discussionsupporting

confidence: 72%

“…The key aim of therapies targeting the poorly compliant or overactive bladder, whatever the aetiology, is to protect the upper urinary tract from damage [1]. Overactive bladder syndrome (OAB) is a common condition (12-17% of general population) with a significant negative impact on quality of life characterized by urgency with or without urge incontinence, frequency and nocturia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gynecological Audit of Intravesical Injection of Botulinum toxin A for the Treatment of Overactive Bladder

Aye¹,

Cho²,

Wong³

et al. 2022

MPOG

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Gynecological Audit of Intravesical Injection of Botulinum toxin A for the Treatment of Overactive Bladder

Aye¹,

Cho²,

Wong³

et al. 2022

MPOG

View full text Add to dashboard Cite

show abstract

“…In all included studies, the authors used BoNT-A, either onabotulinum toxin A (Botox®) [4,6,[11][12][13] or abobotulinum toxin A (Dysport®). [5,7,10] With regard to onabotulinum toxin A, dilution and doses varied from 100 U in 10-20 mL [4,6,11] of injectable saline solution and dose ranged from 50 [13] to 100 U [4,[11][12][13] ; some authors did not report the total doses, but the amount per kilo, 10 U/kg. [6] Regarding abobotulinum toxin A, dilution varied from 500 U in 20 mL [7] to 25 mL [5] of injectable saline solution, and the injected doses varied from 375 to 500 U [7,10] or 8 U/kg.…”

Section: Resultsmentioning

confidence: 99%

“…In urology, BoNT-A was initially used in 1988 in patients with bladder sphincter dyssynergia [4] ; however, its first application to the detrusor of paraplegic patients with neurogenic bladder under intermittent catheterization was reported in 2000. [7] Because of experience in treating neurogenic bladder and sphincteric dysfunction, some authors concluded that detrusor overactivity was the most sensitive component susceptible to BoNT-A treatment; therefore, idiopathic OAB patients would also benefit from this treatment. [6] Recently, some authors have studied this topic, particularly in the pediatric population, and have suggested that BoNT-A is safe and effective for pediatric patients with nonneurogenic OAB that is refractory to conservative treatment.…”

Section: Introductionmentioning

confidence: 99%

The role of botulinum toxin in the management of nonneurogenic overactive bladder in children: Highlights for clinical practice. A systematic review

Câncio Martins Bissaia Barreto,

Táboas Simões,

Gomes Engenheiro

et al. 2024

Curr Urol

View full text Add to dashboard Cite

Overactive bladder (OAB) is the most common voiding dysfunction in children; however, nonneurogenic or idiopathic OAB remains poorly studied. First-line treatment includes conservative measures; however, as many patients are refractory, have adverse effects, or are contraindicated for anticholinergics, new options must be explored. This review covers the use of intravesical botulinum toxin (BoNT) for idiopathic OAB treatment in children, emphasizing its efficacy, safety, differences between toxins, doses, and injection techniques. Clinical results were promising, with all 8 studies reporting good results. All authors used BoNT type A, either onabotulinum or abobotulinum toxin A. Response rates were variable, with full-response percentages of 32%–60%. As proven by the full-response rates of 50%, repeated injections are as safe and effective as first injections. Only a few cases of urinary tract infection, transient urinary retention, and hematuria have been reported, with no major local or systemic adverse effects. Despite these limitations, evidence encourages and supports BoNT type A use as a safe and effective treatment modality for refractory idiopathic OAB in pediatric settings, regardless of dosage and target toxin. To the best of our knowledge, this is the first systematic review of the use of intravesical botulinum toxin type A for idiopathic OAB treatment in children.

show abstract

“…First steps were made in successfully treating children with neurogenic detrusor hyperreflexia by intradetrusor Botox [16]. Since then, several studies demonstrated a safe and effective use of Botox in children suffering from neurogenic detrusor overactivity [2,[17][18][19][20][21][22][23]. In 2006 the first use of Botox in LUTC with mainly symptoms of overactive bladder in the pediatric population was reported as safe and effective [6].…”

Section: Discussionmentioning

confidence: 99%

Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions: A Single Center Experience

Krafft¹,

Hirner²,

Hirner³

et al. 2021

J Urol Ren Dis

View full text Add to dashboard Cite

Introduction:To evaluate efficacy and safety of Botulinum Toxin A (Botox) injection in the detrusor for day-time lower urinary tract conditions with mainly overactive symptoms, we analyzed our uropediatric Botox-treated collective. Materials and Methods:21 Children who received a Botox treatment in our hospital between 2016 and 2020 for refractory day-time lower urinary tract conditions with mainly overactive symptoms with conclusive follow up were analyzed. In all cases we applicated 100 IU Botox.Results: Mean age of patients was 9,19 (±3,0). In 8/21 cases a preoperative urodynamic assessment was available. We reached a median follow up of 289 days (range 34-750). Mean bladder capacity increased from 157 ml (±18.4) to 213 ml (±24.5) (p = 0.001). Mean voiding frequency decreased from 7.4 (±0.61) to 6.2 (±0.55) (p = 0.015). 13/21 Patients (61.9%) encountered a partial or complete therapy response while 8/21 Children (38.1%) showed a therapy failure. Within the responder group, 8/13 Children (61, 5%) experienced an ongoing response. However, 5 Children relapsed on average in 176 days (±45, 5). 3 Children received a repeated injection of Botox. We observed no serious side effects.Discussion/Conclusion: Even though pediatric Botox therapy still lacks standardization; our study indicates a safe and effective use for day-time lower urinary tract conditions with mainly overactive symptoms in children who are resistant to common treatments. Moreover, we found a one-time injection in most cases to be sufficient to improve symptoms in the long term.

show abstract

Intradetrusor injection of botulinum toxin A in children: a 10-year single centre experience

Cited by 7 publications

References 27 publications

Gynecological Audit of Intravesical Injection of Botulinum toxin A for the Treatment of Overactive Bladder

Gynecological Audit of Intravesical Injection of Botulinum toxin A for the Treatment of Overactive Bladder

The role of botulinum toxin in the management of nonneurogenic overactive bladder in children: Highlights for clinical practice. A systematic review

Botulinum Toxin A in Pediatric Day-Time Lower Urinary Tract Conditions: A Single Center Experience

Contact Info

Product

Resources

About